Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
Open Access
- 1 July 2001
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 114 (1) , 78-83
- https://doi.org/10.1046/j.1365-2141.2001.02918.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood, 2000
- Overview: Erythropoiesis, anemia, and the impact of erythropoietinSeminars in Hematology, 2000
- Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade GliomasJournal of Clinical Oncology, 2000
- Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment GuidelinesJournal of Clinical Oncology, 1999
- Thalidomide on the comeback trailNature Medicine, 1999
- The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid MetaplasiaBritish Journal of Haematology, 1999
- Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelinesCytometry, 1998
- Thalidomide as an Anti-TNF-α Inhibitor: Implications for Clinical UseClinical Immunology and Immunopathology, 1996
- Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system [see comments]Blood, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994